Source: http://www.google.fr/patents/US9618478
Timestamp: 2018-01-18 04:24:08
Document Index: 388160030

Matched Legal Cases: ['Application No. 2013', 'Application No. 2014', 'Application No. 201410030477', 'Application No. 201410030477', 'Application No. 14152153', 'Application No. 2014']

Brevet US9618478 - Sample analysis method and solution to be used therein - Google Brevets
Provided are a sample analysis method using capillary electrophoresis capable of enhancing analysis accuracy, a solution for capillary electrophoresis, and a sample analysis kit. The sample analysis method includes separating and/or detecting a substance to be analyzed in a sample through capillary electrophoresis,...http://www.google.fr/patents/US9618478?utm_source=gb-gplus-shareBrevet US9618478 - Sample analysis method and solution to be used therein
Numéro de publication US9618478 B2
Autre référence de publication CN103940887A, EP2757368A1, US20140202858
Numéro de publication 14156738, 156738, US 9618478 B2, US 9618478B2, US-B2-9618478, US9618478 B2, US9618478B2
Citations de brevets (24), Citations hors brevets (5), Classifications (7), Événements juridiques (1)
US 9618478 B2
1. A sample analysis method, comprising:
separating and/or detecting a substance to be analyzed in a sample by capillary electrophoresis in the presence of a running buffer,
wherein the sample comprises hemoglobin, and
the running buffer has a pH of 3.0 to 6.9 and comprises an ionic pseudostationary phase, a pH buffer substance and a non-surfactant-type zwitterionic substance, where the non-surfactant-type zwitterionic substance is a non-surfactant-type betaine.
2. The sample analysis method according to claim 1, further comprising:
introducing the sample into a capillary flow path filled with the running buffer solution; and
separating and/or detecting the substance to be analyzed through capillary electrophoresis by applying a voltage to a whole or to a part of the capillary flow path.
3. The sample analysis method according to claim 1, wherein the sample further comprises the pH buffer substance and the non-surfactant-type zwitterionic substance.
4. The sample analysis method according to claim 1, wherein the sample further comprises the ionic pseudostationary phase, the pH buffer substance, and the non-surfactant-type zwitterionic substance.
5. The sample analysis method according to claim 1, wherein the non-surfactant-type zwitterionic substance does not form a micelle.
6. The sample analysis method according to claim 1, wherein the non-surfactant-type zwitterionic substance has a quaternary ammonium cation and either a sulfo group (—SO3 −) or a carboxyl group (—COO−) at positions not adjacent to each other in the same molecule.
7. The sample analysis method according to claim 1, wherein the pH buffer substance has a pKa or pKb in a pH range of ±2.0 under running conditions.
8. The sample analysis method according to claim 1, wherein the ionic pseudostationary phase is an anionic or a cationic polymer.
9. The sample analysis method according to claim 1, wherein the substance to be analyzed is selected from the group consisting of stable HbA1c (s-HbA1c), hemoglobin A0 (HbA0), hemoglobin Ala (HbA1a), hemoglobin A1b (HbA1b), hemoglobin A1d (HbA1d), hemoglobin Ale (HbA1e), hemoglobin A2 (HbA2), hemoglobin S (HbS, sickle-cell hemoglobin), hemoglobin F (HbF, fetus hemoglobin), hemoglobin M (HbM), hemoglobin C (HbC), hemoglobin D (HbD), hemoglobin E (HbE), methemoglobin, carbamylated hemoglobin, acetylated hemoglobin, aldehyde hemoglobin, and labile HbA1c (l-HbA1c).
10. The sample analysis method according to claim 1, wherein the running buffer solution has a pH of 3.0 to 6.0.
11. The sample analysis method according to claim 1, wherein the ionic pseudostationary phase is a polysaccharide having an anionic group.
The present application claims priority based on Japanese Patent Application No. 2013-9469 filed in Japan on Jan. 22, 2013 and Japanese Patent Application No. 2014-003525 filed in Japan on Jan. 10, 2014, both of which are incorporated herein by reference in their entireties.
In one or a plurality of non-limiting embodiments, examples of the term “substance to be analyzed” as used herein include protein, biological substance, and blood substance. Specific examples of the protein include hemoglobin, albumin, and globulin. In one or a plurality of non-limiting embodiments, examples of the hemoglobin include glycosylated hemoglobin, HbA1c, mutant hemoglobin, minor hemoglobin, and modified hemoglobin. More specific examples thereof include stable HbA1c (s-HbA1c), hemoglobin A0 (HbA0), hemoglobin A1a (HbA1a), hemoglobin A1b (HbA1b), hemoglobin A1d (HbA1d), hemoglobin A1e (HbA1e), hemoglobin A2 (HbA2), hemoglobin S (HbS, sickle-cell hemoglobin), hemoglobin F (HbF, fetal hemoglobin), hemoglobin M (HbM), hemoglobin C (HbC), hemoglobin D (HbD), hemoglobin E (HbE), methemoglobin, carbamylated hemoglobin, acetylated hemoglobin, aldehyde hemoglobin, and labile HbA1c (l-HbA1c). In one or a plurality of non-limiting embodiments, examples of the biological substance and the blood substance include bilirubin, hormone, and metabolite. Examples of the hormone include thyroid-stimulating hormone, adrenocorticotropic hormone, human chorionic gonadotropin, insulin, glucagons, adrenal cortical hormone, epinephrine, norepinephrine, androgen, estrogen, progesteron, aldosterone, and cortisol. In one or a plurality of non-limiting embodiments, examples of the substance to be analyzed in the case of using the above-mentioned ionic pseudostationary phase include glycosylated hemoglobin, mutant hemoglobin, minor hemoglobin, modified hemoglobin, and a combination thereof.
[A13] The sample analysis method described in any one of [A1] to [A12], wherein the sample is capable of containing a substance selected from a group consisting of stable HbA1c (s-HbA1c), hemoglobin A0 (HbA0), hemoglobin A1a (HbA1a), hemoglobin A1b (HbA1b), hemoglobin A1d (HbA1d), hemoglobin A1e (HbA1e), hemoglobin A2 (HbA2), hemoglobin S (HbS, sickle-cell hemoglobin), hemoglobin F (HbF, fetus hemoglobin), hemoglobin M (HbM), hemoglobin C (HbC), hemoglobin D (HbD), hemoglobin E (HbE), methemoglobin, carbamylated hemoglobin, acetylated hemoglobin, aldehyde hemoglobin, and labile HbA1c (l-HbA1c), as a substance to be analyzed.
US5192405 9 sept. 1991 9 mars 1993 Millipore Corporation Process for effecting high efficiency separations by capillary electrophoresis
US5599433 17 janv. 1995 4 févr. 1997 Beckman Instruments, Inc. Capillary electrophoresis of glycosylated proteins
US20060102478 16 nov. 2005 18 mai 2006 Sebia Method for analyzing haemoglobin by capillary electrophoresis, a kit for capillary electrophoresis, and use of a flow inhibitor in said method
US20060210994 15 mars 2005 21 sept. 2006 Joyce Timothy H Microfluidic systems and methods for using microfluidic devices
US20100006436 26 déc. 2007 14 janv. 2010 Sekisui Chemical , Co., Ltd. Hemoglobin measurement method and electrophoresis apparatus
US20100032294 23 avr. 2008 11 févr. 2010 Arkray, Inc. Method for analyzing hemoglobin by capillary electrophoresis and additive used therein
CN102047104A 17 juil. 2009 4 mai 2011 爱科来株式会社 Apparatus and method for analysis by capillary electrophoretic method
CN102128873A 17 janv. 2011 20 juil. 2011 爱科来株式会社 Method for analyzing sample by electrophoresis and use of the same
JP2006145537A Titre non disponible
JP2008032676A Titre non disponible
JP2009109230A Titre non disponible
JPH0557114A Titre non disponible
JPH09510792A Titre non disponible
WO2000063683A1 19 avr. 2000 26 oct. 2000 Target Discovery, Inc. Polypeptide fingerprinting methods, metabolic profiling, and bioinformatics database
WO2008136321A1 23 avr. 2008 13 nov. 2008 Arkray, Inc. Method of analyzing hemoglobin by capillary electrophoresis and additive to be used therein
WO2009062967A1 12 nov. 2008 22 mai 2009 Becton, Dickinson & Company Ms-compatible nonionic or zwitterionic surfactants in free-flow electrophoresis
WO2010010859A1 17 juil. 2009 28 janv. 2010 アークレイ株式会社 Apparatus and method for analysis by capillary electrophoretic method
1 * Bushey et al. (Journal of Chromatography, 480 (1989) 301-310).
2 Chinese Office Action issued in corresponding Chinese Patent Application No. 201410030477.4 dated Jan. 16, 2017.
3 Chinese Office Action issued in corresponding Chinese Patent Application No. 201410030477.4 dated Oct. 29, 2015.
4 Extended European Search Report issued in corresponding European Patent Application No. 14152153A dated Apr. 29, 2014.
5 Office Action issued in corresponding Japanese Patent Application No. 2014-003525 dated Feb. 3, 2015.
Classification internationale C07K1/26, G01N27/447, B01D57/02
Classification coopérative G01N27/44747, C07K1/26, B01D57/02, G01N27/447